TheraVida is a Chapel Hill, North Carolina based clinical stage specialty pharmaceutical company focused on the development of THVD-102 for the treatment of primary focal hyperhidrosis. THVD-102’s systemic approach gives it the unique potential to address patients suffering from both primary focal and secondary generalized hyperhidrosis.

We successfully completed a Phase 2 trial of THVD-102 and licensed the product to Dermavant Sciences for worldwide development.